Exosla Therapeutics is a UK/German pre-clinical biotech company focused on immune-related diseases, including neuroinflammation. It offers a safe and scalable immunotherapy by leveraging the multimodal action of high-performing extracellular vesicles (EVs) from specific monoclonal mesenchymal stem/stromal cell (MSC) lines, which were previously immortalised to supply the full drug life cycle. The scientific and translational efforts are built on over a decade of foundational work by Prof. Bernd Giebel at the University of Duisburg-Essen, a pioneer in the MSC-EV field.
Company Details
- Employees
- 2
- Address
- The Key Challenges In Manufacturing Msc-Sev Products
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.exosla.com/
Exosla Therapeutics Questions
Exosla Therapeutics's website is https://www.exosla.com/
Exosla Therapeutics's LinkedIn profile is https://www.linkedin.com/company/exosla-therapeutics
Exosla Therapeutics has
2 employees.
View email and phone details for 2
employees at Exosla Therapeutics.
Exosla Therapeutics's industry is
Biotechnology Research
Exosla Therapeutics's top competitors are
Stemsight,
Aspire Biosciences,
Crowlight Partners,
Glycostem Therapeutics,
Mursla Bio,
German Society For Extracellular Vesicles,
Amphista Therapeutics Limited,
Maxion Therapeutics,
Analyze & Realize Gmbh,
Microa.
Exosla Therapeutics's categories are Biotechnology Research
